RPRX
Royalty Pharma plc · Healthcare · Medical - Pharmaceuticals
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 146 | 0 | 306.62M | $17.19B | +5 | −4 |
| Q1 2026 | 148 | +6 | 297.67M | $14.26B | +10 | −5 |
| Q4 2025 | 141 | +1 | 305.31M | $11.80B | +2 | — |
| Q3 2025 | 19 | +1 | 173.40M | $6.12B | +2 | −2 |
| Q2 2025 | 16 | 0 | 158.26M | $5.71B | — | — |
| Q1 2025 | 13 | -3 | 61.13M | $1.91B | — | −3 |
| Q4 2024 | 16 | +2 | 77.30M | $1.97B | +2 | — |
| Q3 2024 | 13 | -1 | 62.78M | $1.78B | +1 | −2 |
| Q2 2024 | 14 | — | 58.59M | $1.54B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 16.35M | — | $431.22M | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Viking Global Investors ✦ | 11.97M | — | $315.65M | 1.2% | n/c | 1 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 10.93M | — | $288.28M | 0.5% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 6.85M | — | $180.30M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 6.85M | — | $180.30M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 4.81M | — | $126.82M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 2.35M | — | $61.98M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 2.06M | — | $54.26M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Marshall Wace ✦ | 945.84K | — | $24.94M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 940.03K | — | $24.79M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 785.57K | — | $20.72M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 270.45K | — | $7.13M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 238.99K | — | $6.30M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Wellington Management ✦ | 57.40K | — | $1.51M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Wellington Management ✦ | 57.40K | — | $1.51M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Wellington Management ✦ | 57.40K | — | $1.51M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 33.61K | — | $886,348 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 583 holders, 354.58M shares, $16.55B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 100.00K sh · $6.00M
Officer · 9.23K sh · $540,752
Officer · 1.77K sh · $104,799
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
18.7% of class · View original SEC filing ↗
4.8% of class · View original SEC filing ↗